Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

Turashvili G, Gómez-Hidalgo NR, Flynn J, Gonen M, Leitao MM Jr, Soslow RA, Murali R.

Gynecol Oncol. 2018 Nov 6. pii: S0090-8258(18)31315-5. doi: 10.1016/j.ygyno.2018.10.033. [Epub ahead of print]

PMID:
30413340
2.

Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.

Aloisi A, Casanova JM, Tseng JH, Seader KA, Nguyen NT, Alektiar KM, Makker V, Chiang S, Soslow RA, Leitao MM Jr, Abu-Rustum NR.

Gynecol Oncol. 2018 Oct 1. pii: S0090-8258(18)31240-X. doi: 10.1016/j.ygyno.2018.09.021. [Epub ahead of print]

PMID:
30286945
3.

Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases.

Stolnicu S, Hoang L, Hanko-Bauer O, Barsan I, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Soslow RA.

Mod Pathol. 2018 Sep 26. doi: 10.1038/s41379-018-0123-6. [Epub ahead of print]

PMID:
30258209
4.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

PMID:
30232083
5.

Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.

Schlappe BA, Weaver AL, Ducie JA, Eriksson AGZ, Dowdy SC, Cliby WA, Glaser GE, Soslow RA, Alektiar KM, Makker V, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2018 Nov;151(2):235-242. doi: 10.1016/j.ygyno.2018.08.022. Epub 2018 Aug 31.

PMID:
30177461
6.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Aug 1. doi: 10.1158/1078-0432.CCR-18-0412. [Epub ahead of print]

PMID:
30068706
7.

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.

Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F.

Int J Gynecol Pathol. 2018 Jul 27. doi: 10.1097/PGP.0000000000000538. [Epub ahead of print]

PMID:
30059451
8.

International Endocervical Adenocarcinoma Criteria and Classification: Validation and Interobserver Reproducibility.

Hodgson A, Park KJ, Djordjevic B, E Howitt B, Nucci MR, Oliva E, Stolnicu S, Xu B, Soslow RA, Parra-Herran C.

Am J Surg Pathol. 2018 Jun 5. doi: 10.1097/PAS.0000000000001095. [Epub ahead of print]

PMID:
29877920
9.

Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV.

Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Abu-Rustum NR, Pike MC, Soslow RA.

Gynecol Oncol. 2018 Jul;150(1):56-60. doi: 10.1016/j.ygyno.2018.04.570. Epub 2018 May 30.

PMID:
29859673
10.

Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.

Stolnicu S, Barsan I, Hoang L, Patel P, Chiriboga L, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA.

Am J Surg Pathol. 2018 Aug;42(8):989-1000. doi: 10.1097/PAS.0000000000001090.

PMID:
29851704
11.

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA.

Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24.

PMID:
29804638
12.

Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.

Mueller JJ, Schlappe BA, Kumar R, Olvera N, Dao F, Abu-Rustum N, Aghajanian C, DeLair D, Hussein YR, Soslow RA, Levine DA, Weigelt B.

Gynecol Oncol. 2018 Jul;150(1):127-135. doi: 10.1016/j.ygyno.2018.05.008. Epub 2018 May 22.

PMID:
29793804
13.

BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.

Turashvili G, Grisham RN, Chiang S, DeLair DF, Park KJ, Soslow RA, Murali R.

Histopathology. 2018 Sep;73(3):438-443. doi: 10.1111/his.13651. Epub 2018 Jun 22.

PMID:
29770477
14.

Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens.

Turashvili G, Morency EG, Kracun M, DeLair DF, Chiang S, Soslow RA, Park KJ, Murali R.

Int J Gynecol Pathol. 2018 May 10. doi: 10.1097/PGP.0000000000000519. [Epub ahead of print]

PMID:
29750702
15.

Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas.

Tessier-Cloutier B, Soslow RA, Stewart CJR, Köbel M, Lee CH.

Histopathology. 2018 Aug;73(2):299-305. doi: 10.1111/his.13525. Epub 2018 May 31.

PMID:
29671892
16.

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers.

Mueller JJ, Lajer H, Mosgaard BJ, Bach Hamba S, Morice P, Gouy S, Hussein Y, Soslow RA, Schlappe BA, Zhou QC, Iasonos A, Høgdall C, Leary A, O'Cearbhaill RE, Abu-Rustum NR.

Int J Gynecol Cancer. 2018 Jun;28(5):915-924. doi: 10.1097/IGC.0000000000001263.

PMID:
29561302
17.

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.

Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.

Am J Surg Pathol. 2018 Jun;42(6):791-798. doi: 10.1097/PAS.0000000000001055.

PMID:
29553955
18.

Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.

Ring BZ, Murali R, Soslow RA, Bowtell DDL, Fereday S, deFazio A, Traficante N, Kennedy CJ, Brand A, Sharma R, Harnett P, Samimi G; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12.

PMID:
29531130
19.

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.

Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2018 Mar 6. doi: 10.1097/PGP.0000000000000488. [Epub ahead of print]

PMID:
29517499
20.

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA.

Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

PMID:
29505428
21.

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, Sala E.

AJR Am J Roentgenol. 2018 Apr;210(4):918-926. doi: 10.2214/AJR.17.18254. Epub 2018 Feb 28.

PMID:
29489407
22.

Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer.

Murali R, Delair DF, Bean SM, Abu-Rustum NR, Soslow RA.

J Natl Compr Canc Netw. 2018 Feb;16(2):201-209. doi: 10.6004/jnccn.2017.7066. Review.

PMID:
29439179
23.

A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Soslow RA, Murali R.

Semin Diagn Pathol. 2018 Mar;35(2):95-107. doi: 10.1053/j.semdp.2017.11.007. Epub 2017 Nov 20. Review. No abstract available.

PMID:
29248205
24.

Molecular insights into the classification of high-grade endometrial carcinoma.

Hussein YR, Soslow RA.

Pathology. 2018 Feb;50(2):151-161. doi: 10.1016/j.pathol.2017.09.010. Epub 2017 Dec 13. Review.

PMID:
29246451
25.

ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.

Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, Davidson B, Micci F, Panagopoulos I, Hoang LN, Arias-Stella JA 3rd, Oliva E, Young RH, Hensley ML, Leitao MM Jr, Hameed M, Benayed R, Ladanyi M, Frosina D, Jungbluth AA, Antonescu CR, Chiang S.

Mod Pathol. 2018 Apr;31(4):674-684. doi: 10.1038/modpathol.2017.162. Epub 2017 Dec 1.

PMID:
29192652
26.

The roles of pathology in targeted therapy of women with gynecologic cancers.

Murali R, Grisham RN, Soslow RA.

Gynecol Oncol. 2018 Jan;148(1):213-221. doi: 10.1016/j.ygyno.2017.11.020. Epub 2017 Nov 23. Review.

PMID:
29174566
27.

International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.

Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA.

Am J Surg Pathol. 2018 Feb;42(2):214-226. doi: 10.1097/PAS.0000000000000986.

PMID:
29135516
28.

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.

Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA.

Nat Commun. 2017 Oct 17;8(1):990. doi: 10.1038/s41467-017-01217-9.

29.

Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.

Ducie JA, Eriksson AGZ, Ali N, McGree ME, Weaver AL, Bogani G, Cliby WA, Dowdy SC, Bakkum-Gamez JN, Soslow RA, Keeney GL, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2017 Dec;147(3):541-548. doi: 10.1016/j.ygyno.2017.09.030. Epub 2017 Sep 29.

PMID:
28965698
30.

Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.

Oseledchyk A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, Brown CL, Snyder A, Chi DS, Soslow RA, Abu-Rustum NR, Zivanovic O.

Ann Oncol. 2017 Dec 1;28(12):2985-2993. doi: 10.1093/annonc/mdx525.

PMID:
28950307
31.

Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.

Köbel M, Hoang LN, Tessier-Cloutier B, Meng B, Soslow RA, Stewart CJR, Lee CH.

Am J Surg Pathol. 2018 Jan;42(1):76-83. doi: 10.1097/PAS.0000000000000941.

PMID:
28863077
32.

Inflammatory Pseudotumor Presenting as a Mesosalpingeal Mass.

Stolnicu S, Soslow RA.

Int J Gynecol Pathol. 2018 Sep;37(5):473-476. doi: 10.1097/PGP.0000000000000434.

PMID:
28863066
33.

The genetic landscape of endometrial clear cell carcinomas.

DeLair DF, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, Mohanty AS, Cheng DT, Berger MF, Soslow RA, Weigelt B.

J Pathol. 2017 Oct;243(2):230-241. doi: 10.1002/path.4947. Epub 2017 Sep 5.

34.

Novel Fumarate Hydratase Mutation in Siblings With Early Onset Uterine Leiomyomas and Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome.

Gunnala V, Pereira N, Irani M, Lilienthal D, Pirog EC, Soslow R, Caputo TA, Elias R, Kligman I, Rosenwaks Z.

Int J Gynecol Pathol. 2018 May;37(3):256-261. doi: 10.1097/PGP.0000000000000423.

35.

Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases.

Bennett JA, Weigelt B, Chiang S, Selenica P, Chen YB, Bialik A, Bi R, Schultheis AM, Lim RS, Ng CKY, Morales-Oyarvide V, Young RH, Reuter VE, Soslow RA, Oliva E.

Mod Pathol. 2017 Oct;30(10):1476-1488. doi: 10.1038/modpathol.2017.56. Epub 2017 Jun 30.

36.

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.

Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JM, Danielsen HE, Hoang LN.

Gynecol Oncol. 2017 Sep;146(3):596-602. doi: 10.1016/j.ygyno.2017.06.020. Epub 2017 Jun 21.

PMID:
28647100
37.

High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.

Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.

Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.

38.

BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology.

Chiang S, Lee CH, Stewart CJR, Oliva E, Hoang LN, Ali RH, Hensley ML, Arias-Stella JA 3rd, Frosina D, Jungbluth AA, Benayed R, Ladanyi M, Hameed M, Wang L, Kao YC, Antonescu CR, Soslow RA.

Mod Pathol. 2017 Sep;30(9):1251-1261. doi: 10.1038/modpathol.2017.42. Epub 2017 Jun 16.

39.

Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma.

Geyer FC, Pareja F, Burke KA, Schultheis AM, Hussein YR, Ye J, De Filippo MR, Marchio C, Macedo GS, Piscuoglio S, Lim RS, Toy E, Murali R, Jungbluth AA, Reis-Filho JS, Soslow RA, Weigelt B.

Histopathology. 2017 Sep;71(3):480-487. doi: 10.1111/his.13240. Epub 2017 Jun 16.

40.

A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer.

Eriksson AG, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, Gardner GJ, Zivanovic O, Long Roche K, Sonoda Y, Leitao MM Jr, Jewell EL.

Int J Gynecol Cancer. 2017 May;27(4):743-747. doi: 10.1097/IGC.0000000000000959.

41.

Integrated Molecular Characterization of Uterine Carcinosarcoma.

Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB; Cancer Genome Atlas Research Network, Weinstein JN, Zhang J, Akbani R, Levine DA.

Cancer Cell. 2017 Mar 13;31(3):411-423. doi: 10.1016/j.ccell.2017.02.010.

42.

A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.

Vargas HA, Veeraraghavan H, Micco M, Nougaret S, Lakhman Y, Meier AA, Sosa R, Soslow RA, Levine DA, Weigelt B, Aghajanian C, Hricak H, Deasy J, Snyder A, Sala E.

Eur Radiol. 2017 Sep;27(9):3991-4001. doi: 10.1007/s00330-017-4779-y. Epub 2017 Mar 13.

43.

Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.

Geyer FC, Burke KA, Piscuoglio S, Ng CKY, Papanastasiou AD, Marchiò C, Selenica P, Edelweiss M, Murray MP, Brogi E, Soslow RA, Rubin BP, Norton L, Reis-Filho JS, Weigelt B.

Mol Oncol. 2017 Aug;11(8):913-926. doi: 10.1002/1878-0261.12049. Epub 2017 May 16.

44.

Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.

Schiavone MB, Scelzo C, Straight C, Zhou Q, Alektiar KM, Makker V, Soslow RA, Iasonos A, Leitao MM, Abu-Rustum NR.

Ann Surg Oncol. 2017 Jul;24(7):1965-1971. doi: 10.1245/s10434-017-5816-4. Epub 2017 Mar 3.

45.

Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas.

Sangoi AR, Kshirsagar M, Roma AA, Horvai AE, Chivukula M, Ellenson LH, Fadare O, Folkins AK, Garg K, Hanley K, Longacre TA, Haas J, McCluggage WG, McKenney JK, Nucci MR, Oliva E, Park KJ, Parkash V, Quick CM, Rabban JT, Rutgers JKL, Soslow R, Vang R, Yemelyanova A, Zaloudek C, Beck AH.

Int J Gynecol Pathol. 2017 Jul;36(4):386-392. doi: 10.1097/PGP.0000000000000329.

PMID:
28221217
46.

Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium.

Köbel M, Tessier-Cloutier B, Leo J, Hoang LN, Gilks CB, Soslow RA, Delair D, Stewart CJR, Lee CH.

Int J Gynecol Pathol. 2017 Nov;36(6):555-561. doi: 10.1097/PGP.0000000000000369.

PMID:
28114191
47.

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.

JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.

48.

Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.

Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, Köbel M, Cheng A, Talhouk A, McConechy M, Huntsman DG, McAlpine JN, Soslow RA, Gilks CB.

Am J Surg Pathol. 2017 Feb;41(2):245-252. doi: 10.1097/PAS.0000000000000764.

PMID:
28079598
49.

Abdominal wall endometriosis: differentiation from other masses using CT features.

Yarmish G, Sala E, Goldman DA, Lakhman Y, Soslow RA, Hricak H, Gardner GJ, Vargas HA.

Abdom Radiol (NY). 2017 May;42(5):1517-1523. doi: 10.1007/s00261-016-0998-y.

50.

Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis.

Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, Nougaret S, Sosa RE, Vargas HA, Soslow RA, Abu-Rustum NR, Hricak H, Sala E.

Eur Radiol. 2017 Jul;27(7):2903-2915. doi: 10.1007/s00330-016-4623-9. Epub 2016 Dec 5.

Supplemental Content

Loading ...
Support Center